Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey.
Clicks: 147
ID: 275622
2022
The number and proportion of elderly patients living with chronic hepatitis C are expected to increase in the coming years. We aimed to compare the real-world efficacy and safety of direct-acting antiviral treatment in elderly and younger Turkish adults infected with chronic hepatitis C.In this multicenter prospective study, 2629 eligible chronic hepatitis C patients treated with direct-acting antivirals between April 2017 and December 2019 from 37 Turkish referral centers were divided into 2 age groups: elderly (≥65 years) and younger adults (<65 years) and their safety was compared between 2 groups in evaluable population. Then, by matching the 2 age groups for demographics and pretreatment risk factors for a non-sustained virological response, a total of 1516 patients (758 in each group) and 1244 patients (622 in each group) from the modified evaluable population and per-protocol population were included in the efficacy analysis and the efficacy was compared between age groups.The sustained virological response in the chronic hepatitis C patients was not affected by the age and the presence of cirrhosis both in the modified evaluable population and per-protocol population (P = .879, P = .508 for modified evaluable population and P = .058, P = .788 for per-protocol population, respectively). The results of the per-protocol analysis revealed that male gender, patients who had a prior history of hepatocellular carcinoma, patients infected with non-genotype 1 hepatitis C virus, and patients treated with sofosbuvir+ribavirin had a significantly lower sustained virological response 12 rates (P < .001, P = .047, P = .013, and P = .025, respectively).Direct-acting antivirals can be safely used to treat Turkish elderly chronic hepatitis C patients with similar favorable efficacy and safety as that in younger adults.
Reference Key |
onlen2022efficacythe
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
---|---|
Authors | Önlen, Yusuf;Bal, Tayibe;Çabalak, Mehmet;Çuvalcı Öztoprak, Nefise;Sarı, Nagehan Didem;Kurtaran, Behice;Şenateş, Ebubekir;Gündüz, Alper;Zerdali, Esra;Karsen, Hasan;Batırel, Ayşe;Karaali, Rıdvan;Güner, Rahmet;Yamazhan, Tansu;Köse, Şükran;Erben, Nurettin;İnce, Nevin;Köksal, İftihar;Sarıgül Yıldırım, Figen;Yörük, Gülşen;Kömür, Süheyla;Kaya, Sibel;Esen, Şaban;Günal, Özgür;Esen Yıldız, İlknur;İnan, Dilara;Barut, Şener;Namıduru, Mustafa;Tosun, Selma;Türker, Kamuran;Şener, Alper;Hızel, Kenan;Baykam, Nurcan;Duygu, Fazilet;Akıncı, Esragül;Can, Güray;User, Ülkü;Gül, Hanefi Cem;Akbulut, Ayhan;Çelebi, Güven;Sünnetçioğlu, Mahmut;Karabay, Oğuz;Kumbasar Karaosmanoğlu, Hayat;Sırmatel, Fatma;Tabak, Fehmi; |
Journal | The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology |
Year | 2022 |
DOI | 10.5152/tjg.2022.21271 |
URL | |
Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.